Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivo

Journal of Hypertension

Volumn 29, Issue 2, 2011, Pages 251-256

  Muszkat, Mordechai ^a,b   Kurnik, Daniel ^a   Sofowora, Gbenga G ^a   Wood, Alastair J J ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

vasoconstriction

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; DEXMEDETOMIDINE; PHENYLEPHRINE;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD VESSEL TONE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY MECHANISM; VASOCONSTRICTION; VENOCONSTRICTION;

EID: 78651310335     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283407ffd     Document Type: Article

References (23)

1. Docherty JR. Subtypes of functional alpha1 and alpha2 adrenoceptors. Eur J Pharmacol 1998; 361:1-15.
2. Guimaraes S, Moura D. Vascular adrenceptors: an update. Pharmacol Rev 2001; 53:319-356.
3. Kiowski W, Hulthuren UL, Ritz R, Buhler FR. Alpha 2 adrenoceptor-mediated vasoconstriction of arteries. Clin Pharmacol Ther 1983; 34:565-569.
4. Talke PO, Lobo EP, Brown R, Richardson CA. Clonidine-induced vasoconstriction in awake volunteers. Anesth Analg 2001; 93:271-276.
5. Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ. Postjunctional alphaadrenoceptors and basal limb vascular tone in healthy men. J Physiol 2002; .540.(Pt 3):1103-1110.
6. Muszkat M, Sofowora GG, Wood AJ, Stein CM. Alpha2-adrenergic receptor-induced vascular constriction in blacks and whites. Hypertension 2004; 43:31-35.
7. King D, Etzel JP, Chopra S, Smith J, Cadman PE, Rao F, et al. Human response to a2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther 2005; 77:388-403.
8. Sofowora GG, Dishy V, Landau R, Xie HG, Prasad HC, Byrne DW, et al. Alpha1A-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther 2004; 75:539-545.
9. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and C. Science 1996; 273:803-805.
10. Muszkat M, Sofowora GG, Xie HG, Wood AJJ, Stein CM. Alpha 2Badrenergic receptor 301-303 deletion polymorphism and vascular alpha2 adrenergic receptor response. Pharmacogenet Pharmacogenom 2005; 15:23-28.
11. Muszkat M, Kurnik D, Solus J, Sofowora GG, Xie HG, Jiang L, et al. Variation in the alpha 2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Pharmacogenom 2005; 15:407-414.
12. Muszkat M, Kurnik D, Sofowora GG, Solus J, Xie HG, Harris PA, et al. Desensitization of vascular response in vivo: contribution of genetic variation in the alpha2B-adrenergic receptor subtype. J Hypertens 2010; 28:278-284.
13. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins. 2. Br J Clin Pharmacol 1994; 38:289-305.
14. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins. 1. Br J Clin Pharmacol 1994; 38:181-196.
15. Desai AN, Standifer KM, Eikenburg DC. Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation. J Pharmacol Exp Ther 2004; 311:794-802.
16. Copik AJ, Ma C, Kosaka A, Sahdeo S, Trane A, Ho H, et al. Facilitatory interplay in alpha 1a and beta 2 adrenoceptor function reveals a non-Gq signaling mode: implications for diversification of intracellular signal transduction. Mol Pharmacol 2009; 75:713-728.
17. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-1035.
18. Gonzá lez-Trápaga JL, Nelesen RA, Dimsdale JE, Mills PJ, Kennedy B, Parmer RJ, Ziegler MG. Plasma epinephrine levels in hypertension and across gender and ethnicity. Life Sci 2000; 66:2383-2392.
19. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II: Hemodynamic changes. Anesthesiology 1992; 77:1134-1142.
20. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol 1988; 150:9-15.
21. Hamasaki J, Tsuneyoshi I, Katai R, Hidaka T, Boyle WA, Kanmura Y. Dual a2-adrenergic agonist and a1-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries. Anesth Analg 2002; 94:1434-1440.
22. Etzel JP, Rana BK, Wen G, Parmer RJ, Schork NJ, O'Connor DT, Insel PA. Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Hypertension 2005; 45:1207-1213.
23. Crassous PA, Flavahan S, Flavahan NA. Acute dilation to alpha(2)- adrenoceptor antagonists uncovers dual constriction and dilation mediated by arterial alpha(2)-adrenoceptors. Br J Pharmacol 2009; 158:1344-1355.